Sandoz Group AG / Key word(s): Half Year ResultsSandoz delivers strong H1 2026 results, with outstanding biosimilar growth in the second quarter05-Aug-2026 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. H1 2026 RESULTS H1 net sales up by 5% at constant currencies (CC) to USD 5,761 million Anti-infective B2B[1] headwind on net sales of one percentage point at CC. NOTESThe performance shown in this announcement covers the six-month period ended 30 June 2026 (H1 2026) and the three-month period ended 30 June 2026 (Q2 2026), compared to the six-month period ended 30 June 2025 (H1 2025) and the three-month period ended 30 June 2025 (Q2 2025), respectively. Core EBITDA was USD 1.2 billion (H1 2025: USD 1.0 billion), resulting in a core-EBITDA margin of 20.9% (H1 2025: 20.0%). Core-EBITDA adjustments in H1 2026 were USD 652 million (H1 2025: USD 176 million).